Solving the Capacity Crisis for Viral Vector Manufacturing
Solving the Capacity Crisis for Viral Vector Manufacturing
Viral vectors for gene therapy have shown tremendous clinical promise which has spurred a huge increase in demand for manufacturing space, resulting in a capacity crisis. This is currently delaying the commercialization of these gene therapies for which time to market is critical.
Integrated solutions for viral vectors designed within modular cleanroom facilities streamline manufacturing and reduce time to market. Pall Biotech and G-CON manufacturing have partnered to design and deploy an integrated manufacturing solution to address the current capacity constraints for viral vector manufacturing.
Participants will learn:
- The manufacturing challenges facing the viral vector industry
- The advantages of an integrated manufacturing solution
- How to develop and deploy a new manufacturing facility in 10 months within a modular cleanroom
Moderator
Clive Glover
Director, Cell & Gene Therapy
Pall Biotech
Biography
Presenters
Jeremy Rautenbach
Global Product Manager, Integrated Solutions
Pall Biotech
Joseph Rininger
Director, Cell & Gene Therapy
Latham BioPharm Group
Peter Makowensky
Director, Sales Engineering
G-CON Manufacturing
Maximize Speed to Market Flexibility of Single-Use for Gene Therapy Manufacturing
Listen to Podcast Today
Biotech | Pall Corporation 웨비나 시리즈
This webinar was recorded by BioPharma Asia and first published on their website. https://biopharma-asia.com. It is made available here by kind permission of BioPharma Asia and the presenters.
Hailed as the “next frontier” in cell therapy and regenerative medicine, exosomes are a type of extracellular vesicle and play a key role in the regulation of the intercellular communication processes.
David Haylock of VivaZome will present on upstream production of angiogenic exosomes using the iCELLis® nano fixed bed bioreactor. This will be followed by a presentation by Roberto Ciboldi of Pall Corporation on a platform solution including cell culture, purification and sterile filtration of exosomes.
Participants will be able to:
- Compare the performance of the iCELLis Nano bioreactor to traditional flasks for exosome production from adherent cell culture
- Understand how an integrated end to end platform delivers highly purified and consistently-sized exosomes
- Discover an innovative cGMP scalable manufacturing platform for exosomes